Studie

A Phase 2/3, single arm study to assess safety, tolerability, pharmacokinetics and efficacy of multiple administrations of NI-0501, an anti-interferon gamma monoclonal antibody, in paediatric patients with primary Haemophagocytic Lymphohistiocytosis

Erkrankungsgruppe:

Sonstiges

Organsystem:

Immunsystem

Stadium:

Ersterkrankung

Standort:

Essen

EudraCT:

2012-003632-23

Prüfplan-Code:

NI-0501-04

Phase:

II/III

Prüfsubstanz:

NI-0501

Sponsor:

NovImmune S.A , Switzerland